Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib, Toripalimab, and SBRT in Recurrent SCLC
NCT05162196Phase 2Unknown
- Sponsor
- Wuhan University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 2 trial of niraparib, toripalimab in small cell lung cancer (SCLC), sponsored by Wuhan University. Status: unknown.
02
Drugs
niraparibtoripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05162196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162196.